Publicaciones en colaboración con investigadores/as de Instituto de Investigación Biomédica de Lleida (71)

2023

  1. Clinical Outcomes of Critical COVID-19 in HIV-Infected Adults: A Propensity Score Matched Analysis

    Archivos de Bronconeumologia, Vol. 59, Núm. 11, pp. 772-778

  2. Erratum: Hemorrhage, disseminated intravascular coagulopathy, and thrombosis complications among critically ill patients with COVID-19: An International COVID-19 Critical Care Consortium Study (Critical Care Medicine (2023) 51 (619-631) DOI: 10.1097/CCM.0000000000005798)

    Critical Care Medicine

  3. Hemorrhage, Disseminated Intravascular Coagulopathy, and Thrombosis Complications among Critically Ill Patients with COVID-19: An International COVID-19 Critical Care Consortium Study∗

    Critical Care Medicine, Vol. 51, Núm. 5, pp. 619-631

  4. Impact of the “Zero Resistance” program on acquisition of multidrug-resistant bacteria in patients admitted to Intensive Care Units in Spain. A prospective, intervention, multimodal, multicenter study

    Medicina Intensiva, Vol. 47, Núm. 4, pp. 193-202

  5. Key Factors Associated With Pulmonary Sequelae in the Follow-Up of Critically Ill COVID-19 Patients

    Archivos de Bronconeumologia, Vol. 59, Núm. 4, pp. 205-215

  6. Lurasidone for the treatment of schizophrenia in adult and paediatric populations

    Drugs in Context, Vol. 2023

  7. Metabolomics as a tool to predict the risk of decompensation or liver-related death in patients with compensated cirrhosis

    Hepatology (Baltimore, Md.), Vol. 77, Núm. 6, pp. 2052-2062

  8. Procalcitonin and C-reactive protein to rule out early bacterial coinfection in COVID-19 critically ill patients

    Intensive Care Medicine, Vol. 49, Núm. 8, pp. 934-945

  9. Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly

    Frontiers in Endocrinology, Vol. 14

  10. Risk factors associated with mortality among elderly patients with COVID-19: Data from 55 intensive care units in Spain

    Pulmonology, Vol. 29, Núm. 5, pp. 362-374

  11. Seroprevalence of SARS-CoV-2 in Patients with Multiple Sclerosis under Disease-Modifying Therapies: A Multi-Centre Study

    Journal of Clinical Medicine, Vol. 12, Núm. 23